home / stock / ipsey / ipsey articles

IPSEY Articles, Ipsen SA ADR

Stock Information
Company Name: Ipsen SA ADR
Stock Symbol: IPSEY
Market: OTC
Menu
IPSEY IPSEY Quote IPSEY Short IPSEY News IPSEY Articles IPSEY Message Board
Get IPSEY Alerts

News, Short Squeeze, Breakout and More Instantly...
FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo | Benzinga

Ipsen SA (OTC:IPSEF) (OTC:IPSEY) announced Monday that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Iqirvo (ela...
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis | Benzinga

Ipsen's Iqirvo® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Ch...

Ipsen appoints Keira Driansky as EVP, President of North America | Benzinga

PARIS, FRANCE, 2 May 2024 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointmen...

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases | Benzinga

Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors | Benzinga

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages ...

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook | Benzinga

PARIS, FRANCE, 7 December 2023 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital M...

GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine | Benzinga

ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR ?,? agonist for patients...
International companies to host live webcasts at Deutsche Bank's Depositary Receipts | Benzinga

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("d...

Ipsen nominates Pascal Touchon to its Board of Directors as new independent director | Benzinga

PARIS, FRANCE, 4 September 2023 – Ipsen ((Euronext: IPN, OTC:IPSEY) announced today the co-optation of Pascal Touchon to its Board as an indepen...

Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet | Benzinga

 PARIS, FRANCE, 1 September 2023 – Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, announced today the ...
Next 10